Heart failure & cardiomyopathies
Colchicine in patients with chronic inflammatory cardiomyopathy: rationale and design of the CMP-MYTHiC
Study context
- Population
- Adult patients diagnosed with inflammatory cardiomyopathy (Infl-CMP) by cardiac magnetic resonance imaging (CMRI) or fluorodeoxyglucose-positron emission tomography (FDG-PET) within the prior 3 months, with ventricular arrhythmias (VA) or LVSD/heart failure (HF) phenotypepatients randomized since December 2023, 40 patients per group required
- Participants
- 29 patients
- Planned comparison
- Colchicine compared with placebo
- Primary endpoint
- Proportion of patients alive and free from any clinical, arrhythmic, or imaging worsening, and who demonstrate improvement in either imaging or arrhythmic outcomes
- Follow-up
- 6 months
Methodological details12 Italian centres, rationale and design
- 12 Italian centres
- Rationale and design
No results yet. This paper sets out the design of a trial; its results are to come.
Further findings
Enrolment status
- Patients randomized since December 2023
- Twenty-nine
- Conclusion is expected in 2029
Original publication
Colchicine in patients with chronic inflammatory cardiomyopathy: rationale and design of the CMP-MYTHiC. ESC Heart Fail. Published 24 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →